ARKG vs BIL

ARK Genomic Revolution ETF vs SPDR Bloomberg 1-3 Month T-Bill ETF

Quick take
  • BIL has the lower expense ratio at 0.14% vs 0.75% for ARKG.
  • BIL pays a higher dividend yield (3.95%).

Side-by-side metrics

MetricARKGBIL
Expense ratio
Annual fee. Lower is better.
0.75%0.14%
Dividend yield
Trailing 12-month yield.
0.00%3.95%
AUM
Assets under management — bigger funds are typically more liquid.
$1.24B$46.42B
YTD return
7.21%1.20%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
2.350.00
P/E ratio
Last price
$30.38$91.44
Inception
Issuer
ARKState Street

ARKG top holdings

Top holdings · ARKG
TEMTempus AI Inc Class A common stock9.45%
TWSTTwist Bioscience Corp9.02%
CRSPCRISPR Therapeutics AG8.94%
TXG10x Genomics Inc Ordinary Shares - Class A5.78%
BEAMBeam Therapeutics Inc5.44%
ABSIAbsci Corp4.79%
NTRANatera Inc4.08%
ILMNIllumina Inc4.04%
NTLAIntellia Therapeutics Inc3.83%
PSNLPersonalis Inc3.59%
Sector breakdown · ARKG
Healthcare100.0%

BIL top holdings

Holdings data unavailable for BIL.

About ARKG

ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.2B in assets under management, an expense ratio of 0.75%. Its largest holding is Tempus AI Inc Class A common stock (TEM), which represents 9.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About BIL

BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) is Ultra-short T-Bills, cash-equivalent. Managed by State Street, the fund carries $46.4B in assets under management, an expense ratio of 0.14%, a dividend yield of 3.95%.